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Background: Studies in animals have demonstrated the antiallergenic properties of Chongkukjang (CKJ), a
traditional Korean food made by fermentation of soybean with Bacillus subtilis. CKJ might therefore be
used as an ingredient in a functional food designed to suppress allergies. The purpose of this study was to
investigate the effect of CKJ on histamine-induced skin wheal response in healthy participants.
Methods: A randomized, double-blind, placebo-controlled trial was conducted. Sixty participants (48
women and 12 men) were randomly assigned to one of two groups: One group received 35 g CKJ daily for
12 weeks, and the other received a placebo at the same dosing frequency. A skin prick test with hista-
mine (10 mg/mL) was conducted on the ventral forearm 10 cm from the elbow, and assessed 15 minutes
later. Outcomes included measurement of efﬁcacy [skin wheal response, immunoglobulin E (IgE), his-
tamine, interferon-gamma, interleukin-4, eosinophil, and eosinophil cationic protein (ECP)], and safety
(adverse events, laboratory test results, electrocardiogram, anthropometric values, and vital signs).
Results: Fifty-ﬁve participants (28 in the CKJ group and 27 in the placebo group) completed the study.
After 12 weeks of supplementation, participants in the CKJ group showed a signiﬁcant reduction in
histamine-induced skin wheal areas compared with placebo group (p < 0.05). At 12 weeks, the CKJ group
showed a signiﬁcant improvement in percentage change from baseline in histamine-induced wheal area,
compared with the placebo group (p < 0.05). CKJ did not inﬂuence blood levels of IgE, histamine,
interferon-gamma, interleukin-4, eosinophil, or ECP.
Conclusion: Oral administration of CKJ for 12 weeks resulted in a reduction of the skin wheal response to
histamine, with no apparent adverse effects. Trial registration: ClinicalTrials.gov: NCT01402141.
Copyright © 2015, Korea Food Research Institute, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).nt of Pharmacology, Chonbuk
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titute, Published by Elsevier. This is1. Introduction
Allergic disease is a consequence of exposure to normally
innocuous substances that elicit the activation of mast cells, which
mediate tissue swelling, redness, pain, and respiratory symptoms
[1e6]. A variety of pharmaceutical agents may be used to suppress
the inﬂammation of an allergic response. Since the notion that aan open access article under the CC BY-NC-ND license (http://creativecommons.org/
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potentially reduce or eliminate the need for drugs is highly
attractive, the anti-inﬂammatory and antiallergic activities of
Chongkukjang (CKJ) have been investigated [7].
The traditional Korean food CKJ has the shortest fermentation
period (2e4 days) and is fermented at a high temperature
(40e43C) with Bacillus subtilis. CKJ has its soybean protein
degraded from the protein degradation enzyme, and free amino
acid is produced along with related peptides afterwards. Because of
this, CKJ has its own special characteristics and aroma. It also serves
as a great source of nutrients that provide adequate amounts of
amino acids in Korean peoples’ diets, where rice constitutes a
common and substantial part of most meals [8].
In its long history, CKJ has sometimes been used to treat su-
perﬁcial inﬂammatory skin disorders. The bioactive compounds in
CKJ include the isoﬂavonoids genistein and daidzein [9]. During the
fermentation period, the ﬂavonoid aglycones accumulate through
hydrolysis of the ﬂavonoid glycosides [10]. CKJ also contains poly-
gamma-glutamic acid (gamma-PGA), an anionic polymer
composed of D- and L-glutamic acid units linked through the alpha-
amino and gamma-carboxylic acid groups [11]. Gamma-PGA is
produced by Bacillus subtilis during the fermentation of soybeans
and is not present in humans [12]. Gamma-PGA is water soluble,
biodegradable, edible, and nontoxic, and is therefore compatible
with use in food and cosmetic products [13]. Recent reports also
attribute antiallergic and immunomodulatory activities to gamma-
PGA [7,14e17], although these activities are not conﬁrmed in
humans consuming CKJ.
Histamine is a mediator of the wheal and ﬂare response, one of
the highly irritating symptoms of allergy that impairs quality of life
and prompts sufferers to seek relief in the form of medications. In
the development and comparison of prospective antihistamine
medications, the histamine-induced wheal and ﬂare skin test has
been used most frequently. The histamine-induced wheal and ﬂare
test is based on the planimetric assessment of local swelling caused
by plasma extravasation (wheal) and reﬂex vasodilatation (ﬂare)
after a histamine challenge [18].
The present study, therefore, was carried out to investigate the
antiallergic effects of CKJ, administered orally to human partici-
pants, and assessed using the histamine skin prick test. Findings
from the present study shed light on the efﬁcacy, safety, and un-
derlying mechanisms of CKJ, which are relevant to the develop-
ment of a dietary supplement to treat symptoms of allergy in the
skin.
2. Materials and methods
2.1. Participants
The study participants were recruited from the Clinical Trial
Center for Functional Foods (CTCF2) in Chonbuk National Univer-
sity Hospital (Jeonju, Republic of Korea) between January 2011 and
September 2011. A total of 60 healthy volunteers (12 male, 48 fe-
male; 34.9 ± 12.3 years) participated in this study. The volunteers
had not taken any drugs that might affect histamine response, such
as antihistamines, mast cell stabilizers, or antidepressants for at
least 7 days prior to enrolling in this study. Inclusion criteria were:
(1) healthy volunteers aged 20e80 years and (2) positive response
to the histamine skin prick test (a wheal size > 3 mm). Exclusion
criteria were: (1) a severe generalized skin condition such as
eczema, psoriasis, or atopic dermatitis; (2) a history of severe
allergic reaction; (3) use of oral antihistamines or topical cortico-
steroids in the preceding 3 months; (4) any acute or chronic illness;
(5) cardiovascular disease, liver, or kidney disease; (6) allergies to
soy-containing foods; (7) use of any prescribed or investigativemedication during the 2 months preceding enrollment; (8) exces-
sive use of a drug or alcohol in the preceding 2 months; and (9)
laboratory tests results as well as medical or psychological condi-
tions that could interfere with successful participation in the study
as judged by the investigators.
The study was conducted in accordance with the Declaration of
Helsinki, and written informed consent was obtained from each
participant before the study began. The protocol was approved
by the Functional Foods Institutional Review Board (FFIRB) of
Chonbuk National University Hospital (FFIRB number: 2010-02-
007). The protocol was registered with www.clinicaltrials.gov
(NCT01402141).
2.2. Study design
This current study was conducted under a 12-week, random-
ized, double-blind, placebo-controlled trial to evaluate the safety
and efﬁcacy of CKJ in healthy individuals in Korea. Participants were
recruited through advertisements in local newspapers and the
hospital website and bulletin boards. Candidates were interviewed
and evaluated to determine eligibility. After completing a screening
test, eligible participants were randomized to either the CKJ group
or the placebo group. The treatment period consisted of 1 week of
baseline assessments, 12 weeks of treatment, and 3 weeks of
follow-up, for a total study period of 16 weeks. All participants and
investigators were blinded to the type of treatment received until
completion of the study.
To avoid allocation bias, concealed allocation using a sealed
envelope was employed in this study. A statistician randomized
participants using a computer-generated random table in a 1:1
ratio with block size 2, and clinical research coordinators (CRC)
used the random table to assign the CKJ and placebo treatments.
CKJ or placebo pills were prescribed to the participants every 4
weeks. The CKJ group (n ¼ 30) took 35 g (11.7 g pills per pack, 3
times per day) of freeze-dried CKJ daily for 12 weeks, which was
equivalent to 70 g of fresh CKJ; the placebo group (n ¼ 30) took the
same amount. CKJ and the placebowere provided by the Institute of
Sunchang Fermented Soybean Products (Sunchang, Republic of
Korea). Brieﬂy, white soybeans (Sunchang, Republic of Korea) were
sorted, washed, and soaked inwater for 12 hours at 15C and boiled
for 0.17 hours at 121C. The cooked soybeans were cooled to 40C
and fermented with Bacillus licheniformis SRCM 100027 at 37C for
24 hours. CKJ was freeze-dried using a freeze-dryer (model PVTFD
100R, Ilsinlab, Yangju, Republic of Korea), and then made into pills
(Imshil Herbal Medicine Co., Imshil, Republic of Korea). The placebo
had the same taste and appearance but did not have the principal
ingredient that was present in CKJ. The placebo supplements were
composed primarily of rice and wheat ﬂours.
During a 12-week intervention period, participants were asked
to continue their usual diets and activities and were asked not to
take any other functional foods or dietary supplements. The skin
prick test was performed, and immunoglobulin E (IgE), histamine,
interferon-gamma, interleukin-4, eosinophil, and eosinophil
cationic protein (ECP) were measured before and after the inter-
vention period for both groups. Every 4th week the participants
were asked to report for assessment of any adverse events or any
changes in training, lifestyle, or eating patterns, and to assess pill
compliance.
2.3. Assessments
The skin prick tests with histamine solution, CKJ, and saline
were performed on the forearms using prick lancets. Histaminewas
dissolved in distilled water at 10 mg/mL. A droplet of 10 mg/mL
histamine solution was introduced into the skin by piercing with a
J Ethn Foods 2015; 2: 52e5754sterile lancet. The droplet was gently wiped off after 1 minute, and
the wheal and ﬂare reaction was evaluated under a bright lamp
after 15 minutes. The size of the wheal and ﬂare were outlined with
a thin-tipped marker pen. All tests were carried out by the same
investigator to minimize variability in the application technique.
The area of thewheal and ﬂarewas measured with planimetry, by a
person blinded to the study protocol, and expressed as square
millimeters.
Our primary outcome was the difference in wheal response
induced by the histamine challenge at baseline and at 12 weeks
after randomization. The wheal response was assessed as the mean
diameter or with planimetry at 15 minutes after the challenge. The
secondary outcomes were the mean changes in IgE, histamine,
interferon-gamma, interleukin-4, eosinophil, and ECP. These bio-
markers were checked baseline and 12 weeks.
2.4. Safety measures
Participants reported all unexpected adverse events related to
CKJ intake to the investigator, who then recorded the event on the
individual case report form. Safety assessment was based on clin-
ical laboratory test results, vital signs, anthropometric values,
electrocardiogram, and adverse events. Clinical laboratory tests,
including aspartate transaminase (AST), alanine transaminase
(ALT), total bilirubin, alkaline phosphatase (ALP), g-glutamyl
transferase (GGT), total cholesterol, triglycerides, high-density li-
poprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterolFig. 1. Flow chart used for the study participants. Number of study participants enrolled(LDL-C), glucose, total protein, albumin, blood urea nitrogen (BUN),
creatinine, red blood cell (RBC) count, white blood cell (WBC)
count, hemoglobin, hematocrit, number of platelets, and number of
differentiated cells were performed at baseline and 12 weeks. Vital
signs of each participant were checked while monitoring adverse
events (nausea/vomiting, fatigue, allergic reaction, and any adverse
events related to CKJ) after every visit.
2.5. Statistical analysis
A sample size calculation was performed, using as primary
outcome measure the histamine-induced wheal size, whereby 5.0
square millimeters with a standard deviation of 6.85 was assumed
to represent a clinically relevant difference between the two groups
for alpha set at 5% and power at 80%. This resulted in a required
number of 24 participants in each group. Assuming a dropout rate
of 20%, a total of 60 participants were enrolled in this trial.
Statistical analysis was performed using SAS version 9.0 for
Windows (SAS Institute, Cary, NC, USA). Data were presented as
mean ± SD values. General characteristics were analyzed by the
independent t test or Fisher's exact test. Student paired t test was
used for continuous measures to assess differences before and after
the 12-week intervention period. A linear mixed-effects model was
applied to repeated measures data for each continuous outcome
variable. Fixed effects included treatment group, treatment visit,
and interaction between the treatment group and visits. A value of
p < 0.05 was considered statistically signiﬁcant., allocated, followed, and analyzed shown using the CONSORT 2010 Flow Diagram.
Table 1
Demographic characteristics of the study participants.
CKJ group
(n ¼ 30)
Placebo group
(n ¼ 30)
Total
(n ¼ 60)
p*
Sex (M/F)y 10/20 2/28 12/48 0.021
Age (y) 35.5 ± 11.9 34.2 ± 12.9 34.9 ± 12.3 0.679
Weight (kg) 61.9 ± 11.4 58.7 ± 8.7 60.3 ± 10.2 0.147
Height (cm) 164.2 ± 9.3 161.1 ± 7.3 162.6 ± 8.4 0.209
Values are presented as mean ± standard deviation.
CKJ, Chongkukjang; F, female; M, male.
* Analyzed with independent t test.
y Analyzed with Fisher's exact-test.
Fig. 2. Percentage change from baseline in histamine-induced wheal area. Values are
presented as mean ± standard deviation. Analyzed with independent t test and p-
values compared to placebo.
H.-I. Baek et al / Chungkookjang and wheal response 553. Results
3.1. Participants
The ﬂow chart is summarized in Fig. 1 for the number of par-
ticipants who completed the study. From 87 participants screened
initially, 27 participants were excluded because they failed the in-
clusion criteria by the skin prick test and/or laboratory tests. The
remaining 60 participants were randomly distributed between the
CKJ and placebo groups. Five participants were excluded from the
statistical analysis. One of these participants failed in compliance;
one participant voluntarily withdrew a written informed consent
for personal reasons; one participant experienced a serious adverse
event (SAE); and two participants were excluded from analysis
because of excessive variation, which likely reﬂected an error on
statistical analysis. As a result, 55 participants (CKJ ¼ 28 and
placebo ¼ 27) remained for analysis.
3.2. General characteristics of the participants
Baseline characteristics of participants in the CKJ and placebo
groups are summarized in Table 1. The mean ages of participants in
the CKJ and placebo groups were 35.5 ± 11.9 years and 34.2 ± 12.9
years, respectively. The 60 participants were 34.9 ± 12.3 years old,
overall. There were no signiﬁcant differences in baseline charac-
teristics such as age, weight, and height between the CKJ and pla-
cebo groups.
3.3. Skin prick tests
Results of the skin prick tests are summarized in Table 2. His-
tamine challenge caused amarkedwheal response accompanied by
itching in all participants. The baseline wheal area (prior to
administration of CKJ or placebo) did not differ signiﬁcantly be-
tween groups (14.88 ± 7.44 mm2 vs. 14.16 ± 5.88 mm2, respec-
tively). After 12 weeks of supplementation, participants in the CKJ
group produced a signiﬁcant reduction of histamine-induced
wheals than the placebo group did (p ¼ 0.023).
The percentage change from baseline in histamine-induced
wheal area for the CKJ group and placebo group demonstrated that
they were comparable (Fig. 2). At 12 weeks, the percentage changeTable 2
Histamine-induced wheal area.
CKJ group (n ¼ 28)
Baseline 12 weeks p*
Wheal area (mm2) 14.88 ± 7.44 13.1 ± 5.69 0.121
Values are presented as mean ± SD.
CKJ, Chongkukjang.
* Analyzed with paired t test between baseline and 12 weeks in each group.
y Analyzed with linear mixed-effect model.frombaseline inhistamine-inducedwheal area showedadecrease in
the CKJ group (2.58 ± 41.78 %), whereas the placebo group showed
an increase (30.17 ± 61.99 %). The CKJ group showed a signiﬁcant
improvement compared with the placebo group (p ¼ 0.027).
3.4. Blood proﬁles
Changes in allergenic mediators in blood before and after the
12-week intervention period are shown in Table 3. No signiﬁcant
changes were observed in blood IgE, histamine, interferon-gamma,
interleukin-4, eosinophil, and ECP in either the CKJ or placebo
group at 12 weeks.
3.5. Safety
At every visit, reports of symptoms and adverse effects from
each participant were recorded. One participant in the placebo
group experienced a SAE (a herniated lumbar disc at L5-S1) during
the study, which led them to withdraw from the study. This one
serious adverse effect, as judged by the principal investigator, was
unlikely to be related to the study protocol. No signiﬁcant differ-
ences were found between the two groups. The evaluation was
expanded to include clinical laboratory tests, vital signs, anthro-
pometric vales, and electrocardiogram ﬁndings during the partici-
pants’ visits. All test results were within the normal range, and no
signiﬁcant changes were observed between the CKJ and placebo
groups (data not shown).
4. Discussion
This randomized, double-blind, placebo-controlled trial was
conducted to determine whether taking CKJ could reduce thePlacebo group (n ¼ 27) p for treatment effecty
Baseline 12 weeks p*
14.16 ± 5.88 16.54 ± 5.89 0.101 0.023
Table 3
Blood proﬁles.
CKJ group (n ¼ 28) Placebo group (n ¼ 27) p for treatment effecty
Baseline 12 weeks p* Baseline 12 weeks p*
IgE (IU/mL) 76.54 ± 93.05 69.64 ± 82.26 0.161 70.03 ± 112.46 63.39 ± 98.45 0.084 0.648
Histamine (mg/g creatinine) 0.56 ± 0.55 0.76 ± 0.58 0.144 0.64 ± 0.52 0.81 ± 0.74 0.280 0.901
Interferon-g (IU/mL) 14.4 ± 3.01 17.57 ± 1.9 <.0001 15.79 ± 5.5 18.11 ± 2.24 0.030 0.481
Interleukin-4 (pg/mL) 0.17 ± 0.14 0.27 ± 0.2 0.015 0.57 ± 1.58 0.36 ± 0.79 0.506 0.322
Eosinophil (%) 2.7 ± 2.18 2.58 ± 2.26 0.601 3.33 ± 2.93 2.63 ± 2.59 0.094 0.207
ECP (mg/L) 17.86 ± 17.52 18.77 ± 17.73 0.679 23.21 ± 21.34 21.86 ± 26.59 0.615 0.511
Values are presented as mean ± SD.
CKJ, Chongkukjang; ECP, eosinophil cationic protein; IgE, immunoglobulin E.
* Analyzed with paired t test between baseline and 12 weeks in each group.
y Analyzed with linear mixed-effect model.
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volunteers. We found that consuming CKJ for 3 months resulted
in signiﬁcant attenuation of the skin wheal reaction and that
the CKJ supplement was well tolerated. CKJ supplementation
showed a signiﬁcant improvement in percentage change from
baseline in histamine-induced wheal area compared with the
placebo group.
The CKJ is a Korean fermented soybean containing microor-
ganisms, proteinase, and diverse bioactive compounds, including
isoﬂavones, peptides, and gamma-PGA. Preparations of CKJ are
reported to exert antihypertensive, ﬁbrinolytic, antidiabetic and
anti-inﬂammatory activities. These activities may be attributable to
fermentation products of the Bacillus bacteria through growth
on soy.
The anti-inﬂammatory action of CKJ in the histamine-induced
skin wheal response [7,14e17] may in part represent inhibition of
5-lipoxygenase (5-LOX). The enzyme 5-LOX presents an important
target for anti-inﬂammatory drug development through its role in
leukotriene biosynthesis. Inhibitors of 5-LOX may also suppress
allergy. In a rat model of passive cutaneous anaphylaxis (PCA), CKJ
showed signiﬁcant inhibition. The anti-inﬂammatory activity of
CKJ was evaluated using an arachidonic acid-induced model of
edema in the mouse ear, in which cysteinyl-leukotrienes are major
mediators. In this model, the CKJ dose-dependently inhibited
edema in the ear. The gamma-PGA component of CKJ, in turn, may
signiﬁcantly reduce expression of transient receptor potential A1
(TRPA1) receptors in suburothelial afferents. Histamine-induced
excitation of sensory neurons and PAR-2 activation may activate
or sensitize the TRPV1 receptors. This same pathway may be a
target of the CKJ in attenuation of the histamine-induced skin
wheal response.
Findings in the present study may be limited in that we did not
control for variations in diet or activity levels of the participants;
this uncertainty may be resolved in a future study that includes a
diet and exercise component. Also, we did not evaluate the placebo
effect.
Nevertheless, the signiﬁcant inhibitory effect of CKJ, by oral
administration, on the histamine-induced skinwheal responsemay
have clinical relevance. Many studies have used this test to assess
the relative potency of antihistamines. To the best of our knowl-
edge, no previous study has evaluated the antiallergenic activity of
CKJ in human participants. Therefore, our ﬁndings may contribute
to the development of new cost-effective remedies for mild allergic
diseases.
This study demonstrated the safety and tolerability of CKJ
administered orally in 35-g doses in healthy volunteers. Adminis-
tration of the CKJ in a 12-week regimen resulted in attenuation of
the histamine-induced skin wheal response, suggesting that CKJmay be used to prepare a safe, well-tolerated, and effective func-
tional food for the treatment of allergic conditions.
Conﬂicts of interest
All authors have no conﬂicts of interest to declare.
Acknowledgments
This study was ﬁnancially supported by a contract with the
Ministry for Food, Agriculture, Forestry and Fisheries (MIFAFF)/
Korea Food Research Institute (KFRI)/Institute of Sunchang Fer-
mented Soybean Products and performed by the Clinical Trial
Center for Functional Food of Chonbuk National University Hospital
References
[1] Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004;4:
787e99.
[2] Rivera J and Gilﬁllan AM. Molecular regulation of mast cell activation. J Allergy
Clin Immunol 2006;117:1214e25.
[3] Kawata R, Reddy ST, Wolner B and Herschman HR. Prostaglandin synthase 1
and prostaglandin synthase 2 both participate in activation-induced prosta-
glandin D2 production in mast cells. J Immunol 1995;155:818e25.
[4] Moon TC, Murakami M, Ashraf MD, Kudo I and Chang HW. Regulation of
cyclooxygenase-2 and endogenous cytokine expression by bacterial lipo-
polysaccharide that acts in synergy with c-kit ligand and Fc epsilon receptor I
crosslinking in cultured mast cells. Cell Immunol 1998;185:146e52.
[5] Bochenek G, Nizankowska E, Gielicz A, Swierczynska M and Szczeklik A.
Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast
cell activation by allergen in bronchial asthma. Thorax 2004;59:459e64.
[6] Swindle EJ and Metcalfe DD. The role of reactive oxygen species and nitric
oxide in mast cell-dependent inﬂammatory processes. Immunol Rev
2007;217:186e205.
[7] Choi YH, Lim H, Heo MY, Kwon DY and Kim HP. Anti-inﬂammatory activity of
the ethanol extract of Chungkukjang, Korean fermented bean: 5-lipoxygenase
inhibition. J Med Food 2008;11:539e43.
[8] Shin DH and Jeong DY. Korean traditional fermented soybean products: Jang.
J Ethn Foods 2015;2:2e7.
[9] Kim NY, Song EJ, Kwon DY, Kim HP and Heo MY. Antioxidant and anti-
genotoxic activities of Korean fermented soybean. Food Chem Toxicol
2008;46:1184e9.
[10] Nakajima N, Nozaki N, Ishihara K, Ishikawa A and Tsuji H. Analysis of isoﬂa-
vone content in tempeh, a fermented soybean, and preparation of a new
isoﬂavone-enriched tempeh. J Biosci Bioeng 2005;100:685e7.
[11] Sung MH, Park C, Kim CJ, Poo H, Soda K and Ashiuchi M. Natural and edible
biopolymer poly-gamma-glutamic acid: synthesis, production, and applica-
tions. Chem Rec 2005;5:352e66.
[12] Ashiuchi M, Kamei T, Baek DH, Shin SY, Sung MH, Soda K, Yagi T and
Misono H. Isolation of Bacillus subtilis (chungkookjang), a poly-gamma-
glutamate producer with high genetic competence. Appl Microbiol Bio-
technol 2001;57:764e9.
[13] Shih IL and Van YT. The production of poly-(gamma-glutamic acid) from
microorganisms and its various applications. Bioresour Technol 2001;79:
207e25.
[14] Lee K, Kim SH, Yoon HJ, Paik DJ, Kim JM and Youn J. Bacillus-derived poly-
gamma-glutamic acid attenuates allergic airway inﬂammation through a
H.-I. Baek et al / Chungkookjang and wheal response 57Toll-like receptor-4-dependent pathway in a murine model of asthma. Clin
Exp Allergy 2011;41:1143e56.
[15] Kim TW, Lee TY, Bae HC, Hahm JH, Kim YH, Park C, Kang TH, Kim CJ, Sung MH
and Poo H. Oral administration of high molecular mass poly-gamma-
glutamate induces NK cell-mediated antitumor immunity. J Immunol
2007;179:775e80.
[16] Uto T, Wang X, Sato K, Haraguchi M, Akagi T, Akashi M and Baba M. Targeting
of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticlesinduces antigen-speciﬁc humoral and cellular immunity. J Immunol
2007;178:2979e86.
[17] Kwak CSKM, Kim SA and Lee MS. Cytotoxicity on human cancer cells and
antitumorigenesis of Chungkookjang, a fermented soybean product in DMBA-
treated rats. Korean J Nutr 2006;39:347e56.
[18] Monroe EW, Daly AF and Shalhoub RF. Appraisal of the validity of histamine-
induced wheal and ﬂare to predict the clinical efﬁcacy of antihistamines.
J Allergy Clin Immunol 1997;99:S798e806.
